Search Results for keywords:"hearing requests"

Fisher Clinical Services, Inc. has applied to the Drug Enforcement Administration (DEA) to register as an importer of certain controlled substances. The company intends to import these substances solely for clinical trials. Other types of uses or commercial sales are not allowed under this registration. Interested parties can submit comments or objections electronically by April 16, 2025, and can also request a hearing on the application by the same date.

Aphena Pharma Solutions MD, LLC has applied to the Drug Enforcement Administration (DEA) to be a registered importer of certain controlled substances. These substances will be used internally to manufacture an over-the-counter drug that is approved by the FDA. Interested parties, such as registered bulk manufacturers, can submit electronic comments or objections to this application by April 7, 2025. They can also request a hearing on the application within the same deadline.

The Nuclear Regulatory Commission (NRC) is releasing its regular monthly notice as required under the Atomic Energy Act of 1954. This notice lists amendments to facility operating licenses and combined licenses, determining if they involve no significant hazards consideration (NSHC). Public comments on these amendments are invited until February 20, 2025, and requests for hearings must be submitted by March 24, 2025. The NRC encourages using the Federal rulemaking website for submissions and has provided guidance on electronic submissions and the process for requesting a hearing.

Vici Health Sciences, LLC has applied to become an importer of specific controlled substances to support their research and clinical trials. The Drug Enforcement Administration (DEA) is accepting public comments and objections to this application until February 27, 2025. Interested parties can submit their comments electronically through the Federal eRulemaking Portal. The DEA has specified that this permit will not authorize the import of finished medication forms for sale.

The Securities and Exchange Commission (SEC) has published a notice about an application from Antares Private Credit Fund and Antares Capital Credit Advisers LLC. They are seeking an exemption under the Investment Company Act of 1940 to allow certain investment companies to issue multiple classes of shares with different sales fees and service charges. The application was initially filed in May 2024 and amended in November 2024. The SEC will grant the requested relief unless a hearing is ordered, with hearing requests due by December 23, 2024.

The Nuclear Regulatory Commission (NRC) has issued a regular monthly notice under the Atomic Energy Act, allowing amendments to nuclear facility licenses that pose no significant hazards. The period covered for these amendments is from November 7, 2024, to December 5, 2024. The public can comment on these amendments until January 22, 2025, and request hearings until February 21, 2025. For additional information and to make comments, the NRC encourages using electronic submissions through the federal rulemaking website.

The Securities and Exchange Commission (SEC) is announcing a notice regarding applications for deregistration under Section 8(f) of the Investment Company Act of 1940, specifically for February 2025. A unit investment trust, named FSL Separate Account M, has applied for an order declaring that it is no longer an investment company, as it currently has 96 beneficial owners and does not offer or plan to offer securities. The filing for this application was made on July 1, 2024, and the applicant operates as a private investment fund under section 3(c)(1) of the Act. Public comments or hearing requests can be submitted until March 25, 2025.

The Nuclear Regulatory Commission (NRC) is releasing a monthly notice regarding amendments to facility operating licenses and combined licenses under the Atomic Energy Act of 1954. These amendments involve no significant hazards consideration (NSHC), meaning they don't significantly increase risk or create new accident possibilities. Public comments are invited, and people can request a hearing if they believe they would be impacted by these changes. The NRC emphasizes the use of their electronic filing system for submitting documents related to these proceedings.

The Securities and Exchange Commission (SEC) has released a notice about an application by Guardian Variable Products Trust and Park Avenue Institutional Advisers LLC. They are seeking an exemption from the requirement of the Investment Company Act of 1940 that mandates in-person meetings for approving new or amended sub-advisory agreements. The application was filed on December 13, 2024, and the SEC may hold a hearing if requested by interested parties. Hearing requests must be submitted to the SEC by February 18, 2025.

Janssen Pharmaceuticals Inc. has filed an application with the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances for analytical purposes. Public comments or objections regarding this application are accepted until March 17, 2025. Hearings can also be requested by this date. Comments should be submitted via the Federal eRulemaking Portal, and requests for hearings must be sent to the DEA at specified addresses.